This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million

2 hours ago 4

Jonathan Ponciano, The Motley Fool

Sun, May 24, 2026 astatine 9:39 AM CDT 4 min read

Deep Track Capital disclosed a bargain of 168,066 further Structure Therapeutics (NASDAQ:GPCR) shares successful its May 15, 2026, SEC filing, with an estimated transaction worth of $11.50 cardinal based connected quarterly mean pricing.

What happened

According to its SEC filing dated May 15, 2026, Deep Track Capital accrued its presumption successful Structure Therapeutics by 168,066 shares during the archetypal quarter. The estimated transaction worth was $11.50 million, calculated utilizing the mean closing terms for the quarter. The quarter-end worth of the involvement decreased by $79.69 million, a alteration that includes some stock purchases and banal terms movement.

What other to cognize

This bargain brought the GPCR involvement to 3.37% of the fund's $6.12 cardinal successful reportable U.S. equity holdings arsenic of March 31, 2026.
Top holdings post-filing:
- NASDAQ:GH: $308.35 cardinal (6.36% of AUM)
- NASDAQ:IMVT: $286.33 cardinal (5.91% of AUM)
- NASDAQ:TARS: $252.54 cardinal (5.21% of AUM)
- NASDAQ:PCVX: $249.87 cardinal (5.16% of AUM)
- NASDAQ:AXSM: $185.92 cardinal (3.84% of AUM)
As of Friday, shares were priced astatine $39.19, up 60% implicit the past twelvemonth and good outperforming the S&P 500, which is up astir 28% successful the aforesaid period.

Company Overview

Metric

Value

Price (as of Friday)	$39.19
Market Capitalization	$2.8 billion
Net Income (TTM)	($170.3 million)

Company Snapshot

Structure Therapeutics develops oral small-molecule therapeutics targeting G-protein-coupled receptors (GPCRs) for chronic diseases, with a pb campaigner (GSBR-1290) focused connected type-2 diabetes and obesity, and further programs successful pulmonary and cardiovascular conditions.
The steadfast operates a clinical-stage biopharmaceutical concern model, investing successful probe and improvement to beforehand proprietary cause candidates done objective trials with the purpose of aboriginal commercialization and licensing.
It targets patients with chronic metabolic, pulmonary, and cardiovascular diseases, addressing unmet aesculapian needs successful planetary healthcare markets.

Structure Therapeutics is simply a clinical-stage biotechnology institution headquartered successful South San Francisco, California, with a absorption connected advancing caller oral therapeutics for chronic diseases. The institution leverages expertise successful GPCR-targeted cause find to code important unmet needs successful metabolic and pulmonary indications. Its pipeline and differentiated attack presumption it to vie successful the evolving scenery of oral therapeutics for analyzable diseases.

What this transaction means for investors

By adding to a presumption aft a beardown run, Deep Track is suggesting it believes important value-creating milestones are inactive up for Structure, adjacent aft a astir 60% tally this past year.

The institution has been gathering a compelling lawsuit for aleniglipron, its oral GLP-1 candidate. In March, it reported Phase 2 information showing up to 16.3% value nonaccomplishment astatine 44 weeks, which absorption described arsenic the highest efficacy reported among oral GLP-1 drugs and perchance comparable to injectable therapies. The institution besides received affirmative end-of-Phase 2 feedback from the FDA and remains connected way to statesman Phase 3 studies successful the 3rd 4th of 2026.

CEO Raymond Stevens said the institution is "well positioned" to motorboat its registrational programme and highlighted further amylin and operation therapy opportunities that could broaden the pipeline.

Structure besides remains well-funded, ending the 4th with astir $1.5 cardinal successful cash, currency equivalents, and short-term investments, capable to enactment operations done the extremity of 2028. Ultimately, the cardinal question going guardant is whether aleniglipron tin proceed producing competitory efficacy arsenic it moves into larger studies. If it can, Structure could look arsenic a meaningful subordinate successful the rapidly expanding obesity market.

Read Entire Article